Abstract
Serology assays for standard screening are optimised for use with sera collected from living adults and children. Because of potential changes in the vascular compartments after death, methods used for screening sera from cadaveric organ donors need to be validated before testing these specimens. Serum was separated from blood collected from cadaveric donors within 24 h of death and biochemical parameters measured to detect dilution of protein and haemolysis. In order to demonstrate if any inhibitors that might interfere with the assays were present, pre and post-mortem specimens were spiked with aliquots of human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human T-cell Lymphotropic Virus (HTLV) and T. pallidum-positive sera. Comparison of serum from living subjects with serum obtained post-mortem showed that while the concentration of total protein decreased, concentrations of albumin, immunoglobulin G (IgG) and immunoglobulin M (IgM) remained unchanged. The degree of haemolysis, as measured by free haemoglobin, was within the limits accepted for the Architect analyser. Spiking of pre- and post-mortem specimens with aliquots of HIV, HCV, HBV, HTLV and T. pallidum-positive sera showed no statistical difference in the signal between pre-mortem and post-mortem results when tested on the Abbott Architect analyser. Positive results were obtained in each of a further nine subjects who had tested positive for HIV (n = 1), HCV (n = 8), HBV (n = 1) on pre-mortem serological testing. These findings suggest that the sensitivity of the Abbott Architect serological screening tests is not significantly affected in specimens collected within 24 h of the cessation of life.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brant LJ, Davison KL (2008) Infections detected in English surgical bone and deceased donors (2001–2006) and estimated risk of undetected hepatitis B and hepatitis C virus. Vox Sang 95:272–279
Challine D, Roudot-Thoraval F, Sabatier P, Dubernet F, Larderie P, Rigot P, Pawlotsky JM (2006) Serological viral testing of cadaveric cornea donors. Transplantation 82:788–793
Delmonico FL (2000) Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis 31:781–786
Eastlund T (2000) Hemodilution due to blood loss and transfusion and reliability of cadaveric tissue donor infectious disease testing. Cell Tissue Banking 1:121–127
Eastlund T, Schuller R (1994) The effect of hemodilution on detectability of anti-HIV, anti-HCV and HBsAg: an in vitro study. Paper presented at: Proceedings of the 18th annual meeting, American Association of Tissue Banks (San Francisco)
Food and Drug Administration (2004) Guidance for industry. Recommendations for obtaining a labeling claim for communicable disease donor screening tests using cadavericblood specimens from donors of human cells, tissues and cellular and tissue-based products (HCT/Ps), pp 1–7. http://wwwfdagov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm073972htm
Heck EL, Baxter CR (1994) Guidelines for preventing “dilution false negatives” in in vitro laboratory testing of the donor population. Cornea 13:290–293
Heim A, Wagner D, Rothamel T, Hartmann U, Flik J, Verhagen W (1999) Evaluation of serological screening of cadaveric sera for donor selection for cornea transplantation. J Med Virol 58:291–295
Ison MG (2009) The epidemiology and prevention of donor-derived infections. Adv Chronic Kidney Disease 16:234–241
Kitchen AD, Newham JA (2010) Qualification of serological infectious disease assays for the screening of samples from deceased tissue donors. Cell Tissue Bank. doi:10.1007/s10561-010-9175-7
Madea B, Musshoff F (2007) Postmortem biochemistry. Forensic Sci Int 165:165–171
Miedouge M, Chatelut M, Mansuy J-M, Rostaing L, Malecaze F, Sandres-Saune K, Boudet F, Puel J, Abbal M, Izopet J (2002) Screening of blood from potential organ and cornea donors for viruses. J Med Virol 66:571–575
NHMRC (2007). Organ and tissue donation after death, for transplantation: guidelines for ethical practice for health professionals. Australian Government, Canberra
Singer AL, Kucirka LM, Namuyinga R, Hanrahan C, Subramaniam AK, Segev DL (2008) The high risk donor: viral infections in solid organ transplantation. Current Opinion Organ Transplant 13:400–404
Therapeutic Goods Administration (2000a). Australian code of good manufacturing practice—human blood and tissues, section 827. Australian Government Department of Health and Ageing
Therapeutic Goods Administration (2000b) Australian code of good manufacturing practice—human blood and tissues. p. 26 (point 835)
Turner DPJ, Zuckerman M, Alexander GJM, Waite J, Wreghitt T (1997) Risk of inappropriate exclusion of organ donors by introduction of hepatitis B core antibody testing. Transplantation 63:775–777
Yao F, Seed C, Farrugia A, Morgan D, Cordner S, Wood D, Zheng MH (2007) The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia. Am J Transplant 7:2723–2726
Yao F, Seed C, Farrugia A, Morgan D, Wood D, Zheng MH (2008) Comparison of the risk of viral infection between the living and nonliving musculoskeletal tissue donors in Australia. Transpl Int 21:936–941
Acknowledgments
Financial support for this work was provided by New South Wales Department of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baleriola, C., Johal, H., Robertson, P. et al. Infectious disease screening of blood specimens collected post-mortem provides comparable results to pre-mortem specimens. Cell Tissue Bank 13, 251–258 (2012). https://doi.org/10.1007/s10561-011-9252-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10561-011-9252-6